As of Feb 1, 2001.
Archived by erowid.org on Jan 27, 2002.
(see Misuse of Drugs Act 2001 for the complete act)
From http://www.legislation.hmso.gov.uk/
1. The following substances and products, namely -
- (a) Bufotenine
Cannabinol
Cannabinol derivatives not being dronabinol or its stereoisomers
Cannabis and cannabis resin
Cathinone
Coca leaf
Concentrate of poppy-straw
Eticyclidine
Etryptamine
Lysergamide
Lysergide and other N-alkyl derivatives of lysergamide
Mescaline
Methcathinone
Psilocin
Raw opium
Rolicyclidine
Tenocyclidine
4-Bromo-2,5-dimethoxy-a-methylphenethylamine
N,N-Diethyltryptamine
N,N-Dimethyltryptamine
2,5-Dimethoxy-alpha,4-dimethylphenethylamine
N-Hydroxy-tenamphetamine
4-Methyl-aminorex
(b) any compound (not being a compound for the time being specified in sub-paragraph (a) above) structurally derived from tryptamine or from a ring-hydroxy tryptamine by substitution at the nitrogen atom of the sidechain with one or more alkyl substituents but no other substituent;
(c) the following phenethylamine derivatives, namely -
[erowid note: erowid has added our guesses at the PiHKAL names for the following phenethylamines, but this is a first stab at this and we are not 100% positive about all the IDs, so corrections are welcome]
Allyl(alpha-methyl-3,4-methylenedioxyphenethyl)amine [erowid: aka MDAL, PiHKAL 101]
2-Amino-1-(2,5-dimethoxy-4-methylphenyl)ethanol [erowid: aka BOHD, PiHKAL 16]
2-Amino-1-(3,4-dimethoxyphenyl)ethanol [erowid: aka DME, PiHKAL 57]
Benzyl(alpha-methyl-3,4-methylenedioxyphenethyl)amine [erowid: aka MDBZ, PiHKAL 103]
4-Bromo-ß,2,5-trimethoxyphenethylamine [erowid: aka BOB, PiHKAL 13]
N-(4-sec-Butylthio-2,5-dimethoxyphenethyl)hydroxylamine [erowid: aka HOT-17, PiHKAL 89]
Cyclopropylmethyl(alpha-methyl-3,4-methylenedioxyphenethyl)amine [erowid: aka MDCPM, PiHKAL 104]
2-(4,7-Dimethoxy-2,3-dihydro-1H-indan-5-yl)ethylamine [erowid: aka 2C-G-3, PiHKAL 28 -- If this was what was meant by the British, there is an error on their part. An indane is a 2,3-dihydroindene so there cannot be such a thing as a 2,3-dihydro-indane. The name they probably intended to use was: 2-(4,7-Dimethoxy-2,3-dihydro-1H-inden-5-yl)ethylamine]
2-(4,7-Dimethoxy-2,3-dihydro-1H-indan-5-yl)-1-methylethylamine [erowid: aka G-3, PiHKAL 82 - Exactly the same error as was made in their attempt to list PiHKAL #28, presented in the entry immediately above this one. As written, it makes no sense. What was intended, surely, was: 2-(4,7-Dimethoxy-2,3-dihydro-1H-inden-5-yl)-1-methylethylamine]
2-(2,5-Dimethoxy-4-methylphenyl)cyclopropylamine [erowid: aka DMCPA, PiHKAL 56]
2-(1,4-Dimethoxy-2-naphthyl)ethylamine [erowid: aka 2C-G-N, PiHKAL 31]
2-(1,4-Dimethoxy-2-naphthyl)-1-methylethylamine [erowid: aka G-N, PiHKAL 86]
N-(2,5-Dimethoxy-4-propylthiophenethyl)hydroxylamine [erowid: aka HOT-7, PiHKAL 88]
2-(1,4-Dimethoxy-5,6,7,8-tetrahydro-2-naphthyl)ethylamine [erowid: AKA 2C-G-4, PiHKAL 29]
2-(1,4-Dimethoxy-5,6,7,8-tetrahydro-2-naphthyl)-1-methylethylamine [erowid: aka G-4, PiHKAL 83]
alpha, alpha-Dimethyl-3,4-methylenedioxyphenethylamine [erowid: aka MDPH, PiHKAL 116]
alpha, alpha-Dimethyl-3,4-methylenedioxyphenethyl(methyl)amine [erowid: aka MDMP, PiHKAL 113 ]
Dimethyl(alpha-methyl-3,4-methylenedioxyphenethyl)amine [erowid: aka MDDM, PiHKAL 105]
N-(4-Ethylthio-2,5-dimethoxyphenethyl)hydroxylamine [erowid: aka HOT-2, PiHKAL 87]
4-Iodo-2,5-dimethoxy-a-methylphenethyl(dimethyl)amine [erowid: aka IDNNA , PiHKAL 90]
2-(1,4-Methano-5,8-dimethoxy-1,2,3,4-tetrahydro-6-naphthyl)ethylamine [erowid: aka 2C-G-5, PiHKAL 30]
2-(1,4-Methano-5,8-dimethoxy-1,2,3,4-tetrahydro-6-naphthyl)-1-methylethylamine [erowid: aka G-5, PiHKAL 84]
2-(5-Methoxy-2,2-dimethyl-2,3-dihydrobenzo[b]furan-6-yl)-1-methylethylamine [erowid: aka F-22, PiHKAL 80]
2-Methoxyethyl(alpha-methyl-3,4-methylenedioxyphenethyl)amine [erowid: aka MDMEOET, PiHKAL 112]
2-(5-Methoxy-2-methyl-2,3-dihydrobenzo[b]furan-6-yl)-1-methylethylamine [erowid: aka F-2, PiHKAL 79]
ß-Methoxy-3,4-methylenedioxyphenethylamine [erowid: aka BOH, PiHKAL 15]
1-(3,4-Methylenedioxybenzyl)butyl(ethyl)amine [erowid: Ethyl-K, thanks to N]
1-(3,4-Methylenedioxybenzyl)butyl(methyl)amine [erowid: Methyl-K, thanks to N]
2-(alpha-Methyl-3,4-methylenedioxyphenethylamino)ethanol [erowid: aka MDHOET, PiHKAL 107]
alpha-Methyl-3,4-methylenedioxyphenethyl(prop-2-ynyl)amine [erowid: aka MDPL, PiHKAL 117]
N-Methyl-N-(alpha-methyl-3,4-methylenedioxyphenethyl)hydroxylamine [erowid: aka FLEA, PiHKAL 81]
O-Methyl-N-(alpha-methyl-3,4-methylenedioxyphenethyl)hydroxylamine [erowid: aka MDMEO, PiHKAL 111]
alpha-Methyl-4-(methylthio)phenethylamine [erowid: not found in PiKHAL by me .. analog of 4-MA ; probly not as evil to schedule given 4-MA's toxicity. 2C-T without the 2,5diMeO part. -- Early reports of it were dated 1998, in DEA's Microgram Vol. 31, May, page 150 and June page 174. The initial pharmacological studies were by David Nichols, see European J. Pharm. Vol. 229 pp 31-38 (1992). The British seized some 25,000 tablets (called "Flatliners") which were analyzed as being 4-MTA by the London Toxicology Group.]
ß,3,4,5-Tetramethoxyphenethylamine [erowid: aka BOM, PiHKAL 17]
ß,2,5-Trimethoxy-4-methylphenethylamine [erowid: aka BOD, PiHKAL 14]
(d) any compound (not being methoxyphenamine or a compound for the time being specified in sub-paragraph (a) above) structurally derived from phenethylamine, an N-alkylphenethylamine, alpha-methylphenethylamine, an N-alkyl-alpha-methylphenethylamine, alpha-ethylphenethylamine, or an N-alkyl-alpha-ethylphenethylamine by substitution in the ring to any extent with alkyl, alkoxy, alkylenedioxy or halide substitutents, whether or not further substituted in the ring by one or more other univalent substituents;
(e) any compound (not being a compound for the time being specified in Schedule 2) structurally derived from fentanyl by modification in any of the following ways, that is to say -
- (i) by replacement of the phenyl portion of the phenethyl group by
any heteromonocycle whether or not further substituted in the
heterocycle;
(ii) by substitution in the phenethyl group with alkyl, alkenyl, alkoxy, hydroxy, halogeno, haloalkyl, amino or nitro groups;
(iii) by substitution in the piperidine ring with alkyl or alkenyl groups;
(iv) by substitution in the aniline ring with alkyl, alkoxy, alkylenedioxy, halogeno or haloalkyl groups;
(v) by substitution at the 4-position of the piperidine ring with any alkoxycarbonyl or alkoxyalkyl or acyloxy group;
(vi) by replacement of the N-propionyl group by another acyl group;
(f) any compound (not being a compound for the time being specified in Schedule 2) structurally derived from pethidine by modification in any of the following ways, that is to say -
- (i) by replacement of the l-methyl group by an acyl, alkyl whether
or not unsaturated, benzyl or phenethyl group, whether or not further
substituted;
(ii) by substitution in the piperidine ring with alkyl or alkenyl groups or with a propano bridge, whether or not further substituted;
(iii) by substitution in the 4-phenyl ring with alkyl, alkoxy, aryloxy, halogeno or haloalkyl groups;
(iv) by replacement of the 4-ethoxycarbonyl by any other alkoxycarbonyl or any alkoxyalkyl or acyloxy group;
(v) by formation of an N-oxide or of a quaternary base.
2. Any stereoisomeric form of a
substance specified in paragraph 1.
3. Any ester or ether of a substance specified in paragraph 1 or
2.
4. Any salt of a substance
specified in any of paragraphs 1 to 3.
5. Any preparation or other product containing a substance or
product specified in any of paragraphs 1 to 4, not being a preparation
specified in Schedule 5.
1. The following substances and products, namely -
Acetorphine | Levomoramide |
Alfentanil | Levophenacylmorphan |
Allylprodine | Levorphanol |
Alphacetylmethadol | Lofentanil |
Alphameprodine | Medicinal opium |
Alphamethadol | Metazocine |
Alphaprodine | Methadone |
Anileridine | Methadyl acetate |
Benzethidine | Methyldesorphine |
Benzylmorphine (3-benzylmorphine) | Methyldihydromorphine |
Betacetylmethadol | (6-methyldihydromorphine) |
Betameprodine | Metopon |
Betamethadol | Morpheridine |
Betaprodine | Morphine |
Bezitramide | Morphine methobromide, morphine N-oxide and |
Carfentanil | other pentavalent nitrogen morphine derivatives |
Clonitazene | Myrophine |
Cocaine | Nicomorphine |
Desomorphine | Noracymethadol |
Dextromoramide | Norlevorphanol |
Diamorphine | Normethadone |
Diampromide | Normorphine |
Diethylthiambutene | Norpipanone |
Difenoxin | Oxycodone |
Dihydrocodeinone | Oxymorphone |
O-carboxymethyloxime | Pethidine |
Dihydromorphine | Phenadoxone |
Dimenoxadole | Phenampromide |
Dimepheptanol | Phenazocine |
Dimethylthiambutene | Phencyclidine |
Dioxaphetyl butyrate | Phenomorphan |
Diphenoxylate | Phenoperidine |
Dipipanone | Piminodine |
Dronabinol | Piritramide |
Drotebanol | Proheptazine |
Ecgonine, and any derivative of | Properidine |
ecgonine which is convertible to | Racemethorphan |
ecgonine or to cocaine | Racemoramide |
Ethylmethylthiambutene | Racemorphan |
Etonitazene | Sufentanil |
Etorphine | Thebacon |
Etoxeridine | Thebaine |
Fentanyl | Tilidate |
Furethidine | Trimeperidine |
Hydrocodone | Zipeprol |
Hydromorphinol | 4-Cyano-2-dimethylamino-4,4- |
Hydromorphone | diphenylbutane |
Hydroxypethidine | 4-Cyano-1-methyl-4- |
Isomethadone | phenylpiperidine |
Ketobemidone | 2-Methyl-3-morpholino-1,1-diphenylpropane- |
Levomethorphan | carboxylic acid |
alpha-Methylphenethylhydroxylamine | |
1-Methyl-4-phenylpiperidine-4-carboxylic acid | |
4-Phenylpiperidine-4-carboxylic acid ethyl ester |
2. Any stereoisomeric form of a substance specified in paragraph 1 not being dextromethorphan or dextrorphan.
3. Any ester or ether of a substance specified in paragraph 1 or 2, not being a substance specified in paragraph 6.
4. Any salt of a substance specified in any of paragraphs 1 to 3.
5. Any preparation or other product containing a substance or product specified in any of paragraphs 1 to 4, not being a preparation specified in Schedule 5.
6. The following substances and products, namely -
Acetyldihydrocodeine | Methaqualone |
Amphetamine | Methylamphetamine |
Codeine | Methylphenidate |
Dextropropoxyphene | Nicocodine |
Dihydrocodeine | Nicodicodine (6-nicotinoyldihydrocodeine) |
Ethylmorphine (3-ethylmorphine) | Norcodeine |
Fenethylline | Phenmetrazine |
Glutethimide | Pholcodine |
Lefetamine | Propiram |
Mecloqualone | Quinalbarbitone |
7. Any stereoisomeric form of a substance specified in paragraph 6.
8. Any salt of a substance specified in paragraph 6 or 7.
9. Any preparation or other product containing a substance or product specified in any of paragraphs 6 to 8, not being a preparation specified in Schedule 5.
1. The following substances, namely -
- (a)
Benzphetamine | Mephentermine |
Buprenorphine | Meprobamate |
Cathine | Methylphenobarbitone |
Chlorphentermine | Methyprylone |
Diethylpropion | Pentazocine |
Ethchlorvynol | Phendimetrazine |
Ethinamate | Phentermine |
Flunitrazepam | Pipradrol |
Mazindol | Temazepam |
- (b) any 5, 5 disubstituted barbituric acid not being
quinalbarbitone.
2. Any stereoisomeric form of a
substance specified in paragraph 1 not being
phenylpropanolamine.
3. Any salt of
a substance specified in paragraph 1 or 2.
4. Any preparation or other product containing a substance
specified in any of paragraphs 1 to 3, not being a preparation specified
in Schedule 5.
1. The following substances and products, namely -
Alprazolam | Ketazolam |
Aminorex | Loprazolam |
Bromazepam | Lorazepam |
Brotizolam | Lormetazepam |
Camazepam | Medazepam |
Chlordiazepoxide | Mefenorex |
Clobazam | Mesocarb |
Clonazepam | Midazolam |
Clorazepic acid | Nimetazepam |
Clotiazepam | Nitrazepam |
Cloxazolam | Nordazepam |
Delorazepam | Oxazepam |
Diazepam | Oxazolam |
Estazolam | Pemoline |
Ethyl loflazepate | Pinazepam |
Fencamfamin | Prazepam |
Fenproporex | Pyrovalerone |
Fludiazepam | Tetrazepam |
Flurazepam | Triazolam |
Halazepam | N-Ethylamphetamine |
Haloxazolam |
2. Any stereoisomeric form of a substance specified in paragraph 1.
3. Any salt of a substance specified in paragraph 1 or 2.
4. Any preparation or other product containing a substance or product specified in any of paragraphs 1 to 3, not being a preparation specified in Schedule 5.
1. The following substances, namely -
Atamestane | Methenolone |
Bolandiol | Methyltestosterone |
Bolasterone | Metribolone |
Bolazine | Mibolerone |
Boldenone | Nandrolone |
Bolenol | Norboletone |
Bolmantalate | Norclostebol |
Calusterone | Norethandrolone |
4-Chloromethandienone | Ovandrotone |
Clostebol | Oxabolone |
Drostanolone | Oxandrolone |
Enestebol | Oxymesterone |
Epitiostanol | Oxymetholone |
Ethyloestrenol | Prasterone |
Fluoxymesterone | Propetandrol |
Formebolone | Quinbolone |
Furazabol | Roxibolone |
Mebolazine | Silandrone |
Mepitiostane | Stanolone |
Mesabolone | Stanozolol |
Mestanolone | Stenbolone |
Mesterolone | Testosterone |
Methandienone | Thiomesterone |
Methandriol | Trenbolone |
2. Any compound (not being Trilostane or a compound for the time being specified in paragraph 1 of this Part of this Schedule) structurally derived from 17-hydroxyandrostan-3-one or from 17-hydroxyestran-3-one by modification in any of the following ways, that is to say -
- (a) by further substitution at position 17 by a methyl or ethyl
group;
(b) by substitution to any extent at one or more of positions 1, 2, 4, 6, 7, 9, 11 or 16, but at no other position;
(c) by unsaturation in the carbocyclic ring system to any extent, provided that there are no more than two ethylenic bonds in any one carbocyclic ring;
(d) by fusion of ring A with a heterocyclic system.
3. Any substance which is an ester or
ether (or, where more than one hydroxyl function is available, both an
ester and an ether) of a substance specified in paragraph 1 or described
in paragraph 2 of this Part of this
Schedule.
4. The following
substances, namely -
Chorionic Gonadotrophin
(HCG)
Clenbuterol
Non-human chorionic
gonadotrophin
Somatotropin
Somatrem
Somatropin
5. Any stereoisomeric form of a substance specified or described in
any of paragraphs 1 to 4 of this Part of this
Schedule.
6. Any salt of a
substance specified or described in any of paragraphs 1 to 5 of this Part
of this Schedule.
7. Any
preparation or other product containing a substance or product specified
or described in any of paragraphs 1 to 6 of this Part of this Schedule,
not being a preparation specified in Schedule 5.
1. - (1) Any preparation of one or more of the substances to which this paragraph applies, not being a preparation designed for administration by injection, when compounded with one or more other active or inert ingredients and containing a total of not more than 100 milligrams of the substance or substances (calculated as base) per dosage unit or with a total concentration of not more than 2.5% (calculated as base) in undivided preparations.
(2) The substances to which this paragraph applies are acetyldihydrocodeine, codeine, dihydrocodeine, ethylmorphine, nicocodine, nicodicodine (6-nicotinoyldihydrocodeine), norcodeine and pholcodine and their respective salts.
2. Any preparation of cocaine containing not more than 0.1% of cocaine calculated as cocaine base, being a preparation compounded with one or more other active or inert ingredients in such a way that the cocaine cannot be recovered by readily applicable means or in a yield which would constitute a risk to health.
3. Any preparation of medicinal opium or of morphine containing (in either case) not more than 0.2% of morphine calculated as anhydrous morphine base, being a preparation compounded with one or more other active or inert ingredients in such a way that the opium or, as the case may be, the morphine cannot be recovered by readily applicable means or in a yield which would constitute a risk to health.
4. Any preparation of dextropropoxyphene, being a preparation designed for oral administration, containing not more than 135 milligrams of dextropropoxyphene (calculated as base) per dosage unit or with a total concentration of not more than 2.5% (calculated as base) in undivided preparations.
5. Any preparation of difenoxin containing, per dosage unit, not more than 0.5 milligrams of difenoxin and a quantity of atropine sulphate equivalent to at least 5% of the dose of difenoxin.
6. Any preparation of diphenoxylate containing, per dosage unit, not more than 2.5 milligrams of diphenoxylate calculated as base, and a quantity of atropine sulphate equivalent to at least 1% of the dose of diphenoxylate.
7. Any preparation of propiram containing, per dosage unit, not more than 100 milligrams of propiram calculated as base and compounded with at least the same amount (by weight) of methylcellulose.
8. Any powder of ipecacuanha and opium comprising -
- 10% opium, in powder,
- 10% ipecacuanha root, in powder, well mixed with
- 80% of any other powdered ingredient containing no controlled
drug.
9. Any mixture containing one or more
of the preparations specified in paragraphs 1 to 8, being a mixture of
which none of the other ingredients is a controlled drug.
© Crown copyright 2001 Prepared 20 December 2001